Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 9/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30017745 | 0.82 | SSTR4 (0.48) | SSTR4ESR1SSTR1CYP1A2CYP2A6 | |
| SCHEMBL17755307 | 0.82 | SSTR4 (0.48) | SSTR4ESR1SSTR1CYP1A2CYP2A6 | |
| SCHEMBL17754799 | 0.81 | SSTR4 (0.49) | SSTR4ESR1SSTR1TNKSPARP1 | |
| SCHEMBL24057961 | 0.78 | SSTR4 (0.33) | SSTR4SSTR1 | |
| SCHEMBL16252859 | 0.78 | SSTR4 (0.51) | SSTR4ESR1PARP1 | |
| SCHEMBL22015383 | 0.77 | SSTR4 (0.55) | SSTR4SSTR1CCR4MAPK14LMNA | |
| SCHEMBL13106244 | 0.74 | SSTR4 (0.40) | SSTR4PRMT5ESR1CYP1A2CYP2A6 | |
| SCHEMBL13106356 | 0.73 | ESR1 (0.43) | SSTR4PRMT5ESR1CYP1A2CYP2A6 | |
| SCHEMBL16252850 | 0.73 | SSTR4 (0.45) | SSTR4SSTR1CCR4 | |
| SCHEMBL30018094 | 0.73 | SSTR4 (0.45) | SSTR4SSTR1CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218372-B1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2020-05-20 | — | — | EP | disclosed |
| US-10577336-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-03 | — | — | US | disclosed |
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-09 | — | — | US | disclosed |
| WO-2016075240-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR1, SSTR3 | SSTR4 1/4885PRMT5 1501/4885ESR1 772/4885 |
| US-10577336-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR1, SSTR3 | SSTR4 1/4885PRMT5 1501/4885ESR1 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.